Navigation Links
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
Date:12/1/2011

pleted.  Clinical investigators include Dr. Howard Burris at Sarah Cannon Research Institute, Dr. Roger Cohen at Hospital of the University of Pennsylvania/Abramson Cancer Center and Dr. Keith Flaherty at Massachusetts General Hospital.

About MGA271
MGA271 is a humanized IgG1/kappa monoclonal antibody that recognizes human B7-H3, a novel member of the B7 family of immune regulators.  B7-H3 is an attractive target for immunotherapy, as it is over-expressed in a variety of solid tumors, including prostate, pancreatic, renal cell, ovarian, colorectal, gastric, bladder, and non-small cell lung cancers as well as melanoma. MGA271 has been Fc-optimized using MacroGenics' proprietary Fc-engineering platform to further augment its tumor killing activity. The product's Fc region imparts increased affinity for the human activating Fc-gamma receptor IIIA (Fc-gamma RIIIA, CD16A) and decreased affinity for the inhibitory Fc-gamma RIIB (CD32B).

About MacroGenics
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc. which employ its DART technology.  For more information about MacroGenics, ple
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
2. MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
3. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
4. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
5. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
6. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
7. Intercept Pharmaceuticals and Servier Announce Agreement for Intercepts TGR5 Research Program in Type 2 Diabetes
8. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
9. Zimmer to Establish Asia-Pacific Research and Development Center
10. vRad Selected by Abbeville Area Medical Center for PACS Replacement
11. ETCs Aircrew Training Systems Completes Factory Acceptance Tests for Highly Advanced Suite of Training Equipment for the Republic of Korea Air Force Aeromedical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 Every year ... research to fight heart disease.  Nevertheless, year after year ... ElectroCardioGrams (EKG) as the first test to determine the ... have chest pain or not, even though that technology ... despite the fact that doctors know, (while most patients ...
(Date:2/26/2015)... Mass. , Feb. 26, 2015  Spring ... novel therapeutics for the treatment of Hepatitis B ... the closing of a $22 million financing. Funds ... SB 9200, a novel, broad spectrum antiviral agent ... nucleic acid hybrid (SMNH) chemistry platform, into Phase ...
(Date:2/26/2015)... 26, 2015  Lyric Pharmaceuticals Inc. today announced the ... $20.4 million. The financing, co-led by RiverVest Venture Partners, ... Aperture Venture Partners. Lyric is a ... Wurtman , M.D., M.B.A., President & Chief Executive Officer ... Officer.  In 2014, Lyric closed a seed financing round ...
Breaking Medicine Technology:National Heart Health Month In February 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2
... NEW YORK, Sept. 13, 2011 IMMUNE ... based Therapeutics for the treatment of inflammatory diseases and ... M.D., Ph.D., to the position of Chief Medical Officer.  ... pivotal  role in the development of Bertilimumab, IMMUNE,s phase ...
... DIEGO, Sept. 13, 2011 Sequenom, Inc. (NASDAQ: ... solutions, today announced the Company,s participation at the UBS Global ... in New York City September 19-21, 2011. ... Development, will present on Monday, September 19, 2011 beginning at ...
Cached Medicine Technology:IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 2IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 3Sequenom Announces Participation at UBS Global Life Sciences Conference 2
(Date:2/27/2015)... 27, 2015 The decision to relocate US ... facilities and to make camp more accessible to campers outside ... a Contact Football Camp. The fields are in premier condition ... country,” states Mike de Surville, vice president of US Sports ... of experienced coaches with the passion to create a program ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 RDI-Engineering will ... Mind: Pi Day event on March 14, at Moreno ... services, demonstrations on how to use engineering software and ... will be hosted by Moreno Valley College’s Upward Bound ... Success Center (SSC) in hopes to encourage students to ...
(Date:2/27/2015)... 27, 2015 Is it reasonable – and ... practices and games, and possible to do so without causing ... sports might be at high risk for concern and could ... the issues being addressed by two introductory bills, Int. ... hearing last month in New York City. More specifically, ...
(Date:2/27/2015)... February 27, 2015 Many mattresses ... people’s health. Mercola.com has introduced organic cotton mattresses ... toxic flame retardant chemicals. Dr. Mercola’s Healthy Home ... and better materials. Organic cotton is significantly less ... organic bedding products are made by Naturepedic and ...
(Date:2/27/2015)... According to a Feb. 12, 2015 news release ... treat cancer by killing cancer stem cells, has received orphan ... for use in the treatment of mesothelioma.* According to the ... encourage the development of drugs for the treatment of rare ... decision,” said Melinda Helbock, Founder of The Law Office of ...
Breaking Medicine News(10 mins):Health News:US Sports Camps Football Camps Announce New Contact Football Camp Northeast Location 2Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 3Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 3
... March 23 (HealthDay News) -- A new study helps ... drug therapy. Researchers at the Massachusetts General Hospital ... non-small cell lung cancer, the leading cause of cancer ... with resistance. They also confirmed resistance-related genetic changes ...
... Concordia University have pioneered a computer-based method to detect ... that may open a window on the brain,s electrical ... Detection of Epileptic Seizures," presented at the annual meeting ... the very successful application of this new seizure-detection method. ...
... in French . The human brain loses 5 ... 90 years old. While some cells are lost, the brain is ... results of her most recent clinical study published today in the ... Sylvie Belleville, PhD in neuropsychology, the principal author of this study ...
... will convene in Chicago this week to present new ... detect, treat, prevent and cure osteoarthritis (OA), which affects ... the Segal North American Osteoarthritis Workshop (SNOW) on March ... as those that follow joint trauma, obesity and the ...
... who take statin drugs commonly used to lower cholesterol ... their cancer return than patients who do not take ... March issue of the International Journal of Radiation OncologyBiologyPhysics, ... Oncology (ASTRO). , In the study, 1,681 men with ...
... March 22 (HealthDay News) -- Trauma injury patients who arrive ... no more likely to die than those who arrive on ... contrast with previous research that said patients with health emergencies ... they arrive at the hospital at night or on weekends. ...
Cached Medicine News:Health News:Lung Cancer Evolves With Treatment, Study Finds 2Health News:New way to detect epileptic seizures 2Health News:Subjects at risk of Alzheimer's may now be able to delay the onset of their first symptoms 2Health News:Researchers explore new treatments to end OA 2Health News:Trauma Patients Seem More Likely to Survive on Weekends 2
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: